Skip to content
2000
Volume 10, Issue 1
  • ISSN: 2950-4910
  • E-ISSN: 2950-4902

Abstract

Introduction

A new method for valsartan (VST) estimation in pharmaceutical dosage samples by spectrophotometry was developed.

Methods

The method was based on the formation of coloured dye by the diazotization reaction of 3-amino-2-naphthol with sodium nitrite in an acidic medium to form diazonium compounds, which were then coupled with VST in a basic medium.

Results

The drug sample showed linearity in the range 4.6 - 24.2 μgmL-1, and the λ was found at 432 nm. Sandell’s sensitivity (9.950×10-3), Molar absorbtivity (Ɛ= 4.377×104), regression equation (y= 0.0775x + 0.0041), correlation coefficient (r2= 0.968), detection limit (DL= 0.668) and quantitation limit (QL= 2.024) were evaluated.

Conclusion

The percentage recovery of the drug samples was found to be 100%. This method successfully determined VST in Pharmaceutical dosage samples.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/csch/10.2174/0129504910320544241018094320
2024-10-24
2025-12-09

  • From This Site

    /content/journals/csch/10.2174/0129504910320544241018094320
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. FischerJ. GanellinC.R. Analogue-based Drug Discovery.John Wiley & Sons200647010.1002/3527608001
     [Google Scholar]
  2. BNF 76 (76 ed.)British national formularyPharmaceutical PressEast Smithfield, London2018179
     [Google Scholar]
  3. Valsartan monograph for professionals2019Available from: https://www.drugs.com/monograph/valsartan.html
  4. RandaH.D. article 26. Renin and AngiotensinThe Pharmacological Basis of TherapeuticsMcGraw-Hill Education.New YorkNew York2011
     [Google Scholar]
  5. Diovan- valsartan tablet2019Available from: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c6488119-6547-4abd-bc15-a809b6107d4f#:~:text=Diovan%20(valsartan)%20is%20a%20nonpeptide,the%20AT1%20receptor%20subtype.
  6. Sacubitril and valsartan monograph for professionals2019Available from: https://www.drugs.com/monograph/sacubitril-and-valsartan.html#:~:text=Sacubitril%20and%20valsartan%20(sacubitril%2Fvalsartan,%2Dneprilysin%20inhibitors%20%5BARNIs%5D).
  7. Valsartan pregnancy and breastfeeding warnings2019Available from: https://www.drugs.com/pregnancy/valsartan.html
  8. CohnJ.N. TognoniG. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.N. Engl. J. Med.2001345231667167510.1056/NEJMoa01071311759645
     [Google Scholar]
  9. MakaniH. BangaloreS. DesouzaK.A. ShahA. MesserliF.H. Efficacy and safety of dual blockade of the renin-angiotensin system: Meta-analysis of randomised trials.BMJ2013346jan28 1f36010.1136/bmj.f36023358488
     [Google Scholar]
  10. ZarghiA. AlirezaS. SeyedM.F. HoomanM. Rapid quantification of valsartan in human plasma by liquid chromatography using a monolithic column and a fluorescence detection: Application for pharmacokinetic studies.Sci. Pharm.200876343945010.3797/scipharm.0808‑01
     [Google Scholar]
  11. LiY. ZhaoZ. ChenX. WangJ. GuoJ. XiaoF. HPLC determination of valsartan in human plasma.Yaowu Fenxi Zazhi200020404406
     [Google Scholar]
  12. GonzálezL. AlonsoR.M. JiménezR.M. A high-performance liquid chromatographic method for screening angiotensin II receptor antagonists in human urine.Chromatographia20005211-1273574010.1007/BF02490998
     [Google Scholar]
  13. FrancotteE. DavatzA. RichertP. Development and validation of chiral high-performance liquid chromatographic methods for the quantitation of valsartan and of the tosylate of valinebenzyl ester.J. Chromatogr., Biomed. Appl.19966861778310.1016/S0378‑4347(96)00242‑38953194
     [Google Scholar]
  14. DellaG.T.P. MollyM. GanesanV. A validated stability indicating HPLC method for the determination of Valsartan in tablet dosage forms.J. Appl. Pharm. Sci.201119799
     [Google Scholar]
  15. NawfalI.N.K. HanonI.T. Determination of valsartan in its pharmaceutical preparations using high-performance liquid chromatography technique.Int. J. Health Sci.20226S46087609510.53730/ijhs.v6nS4.9532
     [Google Scholar]
  16. PeleshokK. PiponskiM. AjieE.A. PoliakO. ZarivnaN. DenefilO. LogoydaL. Novel HPLC-UV method for simultaneous determination of valsartan and atenolol in fixed dosage form; Study of green profile assessment.Pharmacia2021681435110.3897/pharmacia.68.e53631
     [Google Scholar]
  17. MarjanP. KaterynaP. LiliyaL. LarysaK. VolodymyrP. UlianaZ. Efficient validated HPLC/UV method for determination of valsartan and atenolol in dosage form and in vitro dissolution studies.Biointerface Res. Appl. Chem.20201066669667510.33263/BRIAC106.66696675
     [Google Scholar]
  18. VinzudaD.U. SailorG.U. ShethN.R. RP-HPLC method for determination of valsartan in tablet dosage form.Int. J. Chemtech Res.2010214611467
     [Google Scholar]
  19. KumarT. H. AshaC. H. New validated stability indicating RP-HPLC method for simultaneous estimation of amlodipine besylate and valsartan in pharmaceutical formulation.IJPSR201910526332643
     [Google Scholar]
  20. PatnaikA. ShettyM. SahooS NayakD. K. VeliyathS. K. A new RP-HPLC method for the determination of valsartan in bulk and its pharmaceutical formulations with it’s stability indicative studies.Pharma Sci Monit.201124353
     [Google Scholar]
  21. SebaiyM.M. El-AdlS.M. BarakaM.M. HassanA.A. El-SayedH.M. Quality by design approach for development and validation of a RP-HPLC method for simultaneous estimation of xipamide and valsartan in human plasma.BMC Chem.2022161708310.1186/s13065‑022‑00864‑436127740
     [Google Scholar]
  22. ŞatanaE. AltınayŞ. GöğerN.G. ÖzkanS.A. ŞentürkZ. Simultaneous determination of valsartan and hydrochlorothiazide in tablets by first-derivative ultraviolet spectrophotometry and LC.J. Pharm. Biomed. Anal.2001255-61009101310.1016/S0731‑7085(01)00394‑611377086
     [Google Scholar]
  23. TatarS. SağlıkS. Comparison of UV- and second derivative-spectrophotometric and LC methods for the determination of valsartan in pharmaceutical formulation.J. Pharm. Biomed. Anal.200230237137510.1016/S0731‑7085(02)00360‑612191724
     [Google Scholar]
  24. SharmaT. SiS.C. A validated gradient stability-indicating LC method for the analysis of valsartan in pharmaceutical dosage form.Int. J. Pharm. Pharm. Sci.20168912810.22159/ijpps.2016v8i9.12581
     [Google Scholar]
  25. PiaoZ.Z. LeeE.S. TranH.T.T. LeeB.J. Improved analytical validation and pharmacokinetics of valsartan using HPLC with UV detection.Arch. Pharm. Res.20083181055105910.1007/s12272‑001‑1268‑418787797
     [Google Scholar]
  26. SreejanardhananV. ShineS.R.P. SREEJANARDHANAN.V SHINE SUDEV RP UFLC method for estimation of valsartan chemometricaly.World J Adv Res Rev.202318241542610.30574/wjarr.2023.18.2.0847
     [Google Scholar]
  27. HaqueA. IqbalM. AlamoudiM. AlamP. A selective and accurate lc-ms/ms method for simultaneous quantification of valsartan and hydrochlorothiazide in human plasma.Separations202310211913110.3390/separations10020119
     [Google Scholar]
  28. MylnikovP.Y. ShchulkinA.V. SeleznevS.V. PravkinS.K. AbalenikhinaY.V. YakushevaE.N. Development and validation of a method for quantification of lisinopril, indapamide, metoprolol, valsartan, and amoldipine in human blood serum by HPLC-MS/MS.Pharm. Chem. J.202458350751110.1007/s11094‑024‑03171‑5
     [Google Scholar]
  29. FaroqO.Q. AkramA.H. KaleM.Q. AhmedJ.M.A. Development and validation of stability indicating nanodrop 2000c UV-vis method for determination of valsartan in pharmaceutical formulations.J Pharm Neg Res202314310.47750/pnr.2023.14.03.120
     [Google Scholar]
  30. BadreldinH.A. KorayemG.B. AlenazyB.A. AljohaniM.H. AlshayaO.A. Al SulaimanK. AlabdelmuhsinL. AlenaziH. AlmutairiD.M. AlanaziF. AlobathaniS.K. AlqannamG.M. AlmadaniO. AljuhaniO. HafizA. AljowaieG. BashaE. AlqahtaniT. AlhusseinM. Real-world analysis of integration of sacubitril/valsartan into clinical practice in Saudi Arabia.Medicine (Baltimore)202310251e3669910.1097/MD.000000000003669938134075
     [Google Scholar]
  31. CagigalE. GonzálezL. AlonsoR.M. JiménezR.M. Experimental design methodologies to optimise the spectrofluorimetric determination of losartan and valsartan in human urine.Talanta20015461121113310.1016/S0039‑9140(01)00379‑418968334
     [Google Scholar]
  32. GuptaK.R. WadodkarA.R. WadodkarS.G. UV Spectrophotometric methods for estimation of Valsartan in bulk and tablet dosage form.Int. J. Chemtech Res.20102985989
     [Google Scholar]
  33. MonikaL. J. ManojV. G. ShripadK.T. ManishS. J. Development and validation of spectrophotometric methods for simultaneous estimation of valsartan and hydrochlorothiazide in tablet dosage formIntern J Spectrosc.201487381910.1155/2014/873819
     [Google Scholar]
  34. SrideviR. BadalK. M. SameerG. N. Simultaneous spectrophotometric determination of valsartan and ezetimibe in pharmaceuticals.Tropical J Pharm Res.2011106809815
     [Google Scholar]
  35. MadhaviL. ShireeshaM. TuljaraniG. Spectrophotometric estimation of valsartan and benazepril hydrochloride in pure and pharmaceutical formulations.Intern J ChemTech Res.20113418301834
     [Google Scholar]
  36. SivasankaraG.R. VenkatS.R. VardhanS.V.M. RamachandranD. Development and validation of new UV-spectrophotometric assay method for valsartan in pure and in formulations.J. Chem. Pharm. Res.201357229232
     [Google Scholar]
  37. MallegowdaS.M. DeepakumariH.N. RevanasiddappaH.D. S. M. Mallegowda Spectrophotometric determination of valsartan using p-chloranilic acid as π-acceptor in pure and in dosage forms.J. Appl. Pharm. Sci.20133111311610.7324/JAPS.2013.30122
     [Google Scholar]
  38. KamalA.H. MarieA.A. HammadS.F. Validated spectrophotometric methods for simultaneous determination of nebivolol hydrochloride and valsartan in their tablet.Microchem. J.202015510474110.1016/j.microc.2020.104741
     [Google Scholar]
  39. RaulS.K. PadhyG.K. KrishnaP.R. PriyaB.U.M. UV Spectrophotometric method development and validation for the estimation of valsartan in bulk and pharmaceutical dosage form.Asian Pharm Anal.20166314715210.5958/2231‑5675.2016.00023.5
     [Google Scholar]
  40. StolarczykM. ApolaA. MaślankaA. KwiecieńA. OpokaW. Spectrophotometric method for simultaneous determination of valsartan and substances from the group of statins in binary mixtures.Acta Pharm.201767446347810.1515/acph‑2017‑003129337671
     [Google Scholar]
  41. KaterynaP. BohdanaB. LiubomyrK. TetyanaK. OlhaP. LiliyaL. Non- extractive spectrophotometric determination of valsartan in pure form and in pharmaceutical products by ion-pair complex formation with bromophenol blue and methyl red.Pharmacia.202168485185810.3897/pharmacia.68.e73559
     [Google Scholar]
  42. PeleshokK. PoliakO. KryskiwL. SarpongA. F. ZarivnaN. KorobkoD. ZahrychukH. HorlachukN. SverstiukA. LevytskaL. LogoydaL. Development and validation of spectrophotometric method for simultaneous estimation of valsartan and atenolol in binary mixtures: Application to tablets analysis.Pharmakeftiki.2021335260
     [Google Scholar]
  43. LotfyH.M. HegazyM.A. MowakaS. MohamedE.H. Novel spectrophotometric methods for simultaneous determination of amlodipine, valsartan and hydrochlorothiazide in their ternary mixture.Spectrochim. Acta A Mol. Biomol. Spectrosc.201514049550810.1016/j.saa.2014.12.09625638433
     [Google Scholar]
  44. TajaneS. T. Estimation of valsartan in pharmaceutical formulation by area under curve spectrophotometric method.Int. J Adv Pharm201807010410.7439/ijap.v7i1.4550
     [Google Scholar]
  45. EbrahimiM. SohrabiM.R. MotieeF. DavalloM. L and D enantiomer binary mixture determination simultaneously by spectrophotometric method without separation step based on artificial neural network and least squares support vector machine in valsartan pharmaceutical production.Optik (Stuttg.)202124716801110.1016/j.ijleo.2021.168011
     [Google Scholar]
  46. SalihR.F. RashidQ.N. Spectrophotometric determination of valsartan in pure form and in its pharmaceutical preparations.Al-Qadisiyah Journal of Pure Science202126423924610.29350/qjps.2021.26.4.1317
     [Google Scholar]
  47. SandhyaraniK. Visible spectrophotometri determination of valsartan in pharmaceutical formulations. Intern. J. Novel Res. Develop.202176198203
     [Google Scholar]
  48. MagdyR. HemdanA. Abdel GhanyM. FaresN. Determination of sacubitril and valsartan binary mixture using different eco-friendly spectrophotometric approaches with or without regression equations; greenness and whiteness assessments.Archives of Pharm. Sci. Ain Shams University20237111810.21608/aps.2023.170188.1102
     [Google Scholar]
  49. AashutoshA.D. PragatiG.K. PoojaP.N. GurappaK.D. Green analytical UV-Vis spectrophotometric method development of valsartan by using hydrotropic agent.Asian J. Res. Chem202316531331810.52711/0974‑4150.2023.00051
     [Google Scholar]
  50. GayatriD. SaurabhK. RupaliH. ShankarD. HarshalT. Analytical method development by using uv-spectrophotometer for estimation of valsartan in bulk.IJPQA.2024152854860
     [Google Scholar]
/content/journals/csch/10.2174/0129504910320544241018094320
Loading
Developing a New Method for the Estimation of Valsartan (VST) in Pharmaceutical Dosage Samples by using Diazotization and Coupling Reactions Spectrophotometrically
Curr Spectrosc Chromatogr 10, E29504910320544 (2024); https://doi.org/10.2174/0129504910320544241018094320
/content/journals/csch/10.2174/0129504910320544241018094320
/content/journals/csch/10.2174/0129504910320544241018094320
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): 3-amino-2-naphthol; diazotization; pharmaceutical dosage samples; regression; spectrophotometry; Valsartan (VST)
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test